Examining outcomes related to suicidality in hospitalized patients with depression

Patient Characteristics, Validity of Clinical Diagnoses and Outcomes Associated With Suicidality in Inpatients With Symptoms of Depression (OASIS-D)

Observational Charite University, Berlin, Germany · NCT04404309

This study is trying to understand how suicidal thoughts change over time in hospitalized patients with depression to help improve their treatment.

Quick facts

Study typeObservational
Enrollment3331 (estimated)
Ages18 Years to 75 Years
SexAll
SponsorCharite University, Berlin, Germany Academic / other
Locations1 site (Berlin-Mitte)
Trial IDNCT04404309 on ClinicalTrials.gov

What this trial studies

This observational cohort study investigates the outcomes associated with suicidality in inpatients aged 18 to 75 years who are experiencing unipolar depressive episodes. It includes three cohorts: those with any form of unipolar depression, those with moderate to severe depression and suicidal tendencies, and those with persistent suicidal tendencies after 48 hours of hospitalization. The study aims to collect data at multiple time points over a 6-month period to better understand the remission or recurrence of suicidal symptoms in the context of depression. The findings are expected to inform future interventions and improve treatment strategies for affected individuals.

Who should consider this trial

Good fit: Ideal candidates are inpatients aged 18 to 75 with a clinical diagnosis of unipolar depression, particularly those exhibiting suicidal tendencies.

Not a fit: Patients with depressive episodes related to bipolar disorder or secondary causes, as well as those outside the age range of 18 to 75, may not benefit from this study.

Why it matters

Potential benefit: If successful, this study could enhance understanding of suicidal behavior in depressed patients, leading to improved treatment options.

How similar studies have performed: Other studies have explored similar themes regarding suicidality in depression, but this specific approach is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria
Inclusion Criteria:

For Population 1

1.any form of unipolar depressive episode

For Population 2

1. clinical diagnosis of a moderate or severe unipolar depressive episode
2. clinically diagnosed suicidal tendencies that persist for at least 48 hours after admission to hospital
3. Written consent to participate in the study

For Population 3

1. Diagnosis of a moderate or severe unipolar depressive disorder through the structured research interview "Mini International Neuropsychiatric Interview" (M.I.N.I.)
2. Suicidality with a value \> / = 1 for item 2 (passive suicidality) OR item 3 (active suicidality) based on the research interview "Sheehan Suicidality Tracking Scale" (S-STS)
3. Written consent to participate in the study

Exclusion Criteria:

* Patients younger than 18 years or older than 75 years
* No clinical diagnosis of a depressive episode
* Depressive episode in the context of a bipolar disorder- secondary depression as a result of physical illness or substance use
* severe physical symptoms of disease that make participation in the study impossible
* Pregnancy
* not being able to understand the study processes
* incapable of giving informed consent
* no authorization to give consent due to (limited) incapacity

Where this trial is running

Berlin-Mitte

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions DepressionDepression ModerateDepression SevereSuicidal and Self-injurious BehaviorSuicidal IdeationSuicide, AttemptedSuicidality
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.